Overview

Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Zoledronic acid selectively binds to bone and protects it from being metastasized by tumor cells. This study evaluates the safety and efficacy of zoledronic acid when added to standard therapies in breast cancer patients with metastatic bone lesions.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Diphosphonates
Zoledronic Acid